|
|
|
|
BiomedReports: FDA Calendar Updates for Eisai (OTC:ESALY), King Pharma (NYSE:KG), Myriad Pharma (NASDAQ:MYRX)
(M2 PRESSWIRE via COMTEX) -- BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has new updates to it's database of...
|
|
|
King Pharmaceuticals Inc announces receipt of complete response letter from FDA for Acurox
(M2 EQUITYBITES via COMTEX) -- KG | Quote | Chart | News | PowerRating -- Acura Pharmaceuticals Inc (Nasdaq:ACUR) and King Pharmaceuticals Inc (NYSE:KG) declared on Thursday that the pharmaceutical companies have received a complete...
|
|
|
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Pa
Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical...
|
|
|
Eisai to file new Aricept formulation, wants out of Pfizer pact
Eisai is looking to file a new formulation of Aricept in the next couple of months and is confident about terminating its collaboration with Pfizer, the Japanese drugmakers marketing partner for the Alzheimer's disease blockbuster.
|
|
|
Acura And King Receive FDA Complete Response Letter Regarding Acurox(R)
Acura Pharmaceuticals, Inc.(Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug ...
|
|
|
CombinatoRx and Neuromed Sign Merger Agreement
- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, MA and VANCOUVER, BC, July 2 /PRNewswire/ - CombinatoRx, Incorporated and...
|
|
|
POZEN Submits New Drug Application For VIMOVO' (PN 400)
POZEN Inc.(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
POZEN Inc.(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric...
|
|
|
Acura Pharma, King Pharma Receive FDA Complete Response Letter Regarding NDA For Acurox - Quick Facts
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Acura Pharmaceuticals, Inc.(ACUR: News ) and King Pharmaceuticals, Inc. (KG: News ) announced that the U.S. Food and Drug Administration has issued a...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , President & CEO: Haruo Naito 1. Sustained Release Tablets Eisai has completed a Phase III study of Aricept 23 mg sustained release (SR)...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept for Enhancing Patie
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime...
|
|
|
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Companies mentioned in this article: King Pharmaceuticals, Inc.PALATINE, Ill. and BRISTOL, Tenn., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
Companies mentioned in this article: Eisai Co., Ltd.TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America ...
|
|
|
Photocure submits application for marketing approval for Hexvix in USA to the FDA
--Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence...
|
|
|
Photocure submits application for marketing approval for Hexvix, in USA to the FDA
Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence...
|
|
|
PPD Confirms Takeda Receives FDA Complete Response For Alogliptin
PPD, Inc.(NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a...
|
|
|
CombinatoRx and Neuromed Sign Merger Agreement
- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, MA and VANCOUVER, BC, July 2 /PRNewswire/ - CombinatoRx, Incorporated and...
|
|
|
Acura (ACUR) & King Pharmaceuticals (KG) Receive Complete Response Letter From FDA for Acurox
Acura Pharmaceuticals, Inc.(Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug ...
|
|
|
CombinatoRx And Neuromed Sign Merger Agreement
CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced they have entered into a definitive merger agreement under which CombinatoRx and Neuromed will merge in...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
ity Research highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG | Quote | Chart | News | PowerRating) as the Bull of the Day and Palm, Inc. (Nasdaq: PALM | Quote | Chart | News | PowerRating) the Bear of the Day. In...
|
|
|
FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences
Below is a summary of updates to the , which includes a database of over 200 entries.I originally created this calendar to track companies with pending new drug, biological agent, or medical device new product decisions...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
http://www.profit.zacks.com/ CHICAGO--(Business Wire)-- Zacks Equity Research highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the Bull of the Day and Palm, Inc. (Nasdaq:PALM) the Bear of the Day. In addition, Zacks Equity...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re,
BusinessWire - Zacks Equity Research highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the Bull of the Day and Palm, Inc. (Nasdaq: PALM) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Everest Re (NYSE...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals
highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the and Palm, Inc. (Nasdaq:PALM) the. In addition, provides analysis on Everest Re (NYSE:RE), Ace Limited (NYSE:ACE) and Montpelier (NYSE:MRH). Full analysis of all these stocks...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
CHICAGO--(BUSINESS WIRE)-- highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the and Palm, Inc. (Nasdaq: PALM) the. In addition, provides analysis on Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH).
|
